Per citar aquest document: http://ddd.uab.cat/record/145976
Clinical use of tolerogenic dendritic cells-harmonization approach in european collaborative effort
Brinke, Anja ten (Sanquin Blood Supply (Amsterdam))
Hilkens, Catharien M.U. (Newcastle University. Institute of Cellular Medicine)
Cools, Nathalie (University of Antwerp. Vaccine & Infectious Disease Institute)
Geissler, Edward K. (University Hospital Regensburg. Department of Surgery)
Hutchinson, James A. (University Hospital Regensburg. Department of Surgery)
Lombardi, Giovanna (King's College (London). MRC Centre for Transplantation)
Lord, Phillip (Newcastle University. School of Computing Science)
Sawitzki, Birgit (Charité University Medicine (Berlin). Institute of Medical Immunology)
Trzonkowski, Piotr (Medical University of Gdansk. Department of Clinical Immunology and Transplantology)
Ham, S. Marieke van (Sanquin Blood Supply (Amsterdam))
Martínez Cáceres, Eva María Cabeza (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia

Data: 2015
Resum: The number of patients with autoimmune diseases and severe allergies and recipients of transplants increases worldwide. Currently, these patients require lifelong administration of immunomodulatory drugs. Often, these drugs are expensive and show immediate or late-occurring severe side effects. Treatment would be greatly improved by targeting the cause of autoimmunity, that is, loss of tolerance to self-antigens. Accumulating knowledge on immune mechanisms has led to the development of tolerogenic dendritic cells (tolDC), with the specific objective to restrain unwanted immune reactions in the long term. The first clinical trials with tolDC have recently been conducted and more tolDC trials are underway. Although the safety trials have been encouraging, many questions relating to tolDC, for example, cell-manufacturing protocols, administration route, amount and frequency, or mechanism of action, remain to be answered. Aiming to join efforts in translating tolDC and other tolerogenic cellular products (e. g. , Tregs and macrophages) to the clinic, a European COST (European Cooperation in Science and Technology) network has been initiated-A FACTT (action to focus and accelerate cell-based tolerance-inducing therapies). A FACTT aims to minimize overlap and maximize comparison of tolDC approaches through establishment of minimum information models and consensus monitoring parameters, ensuring that progress will be in an efficient, safe, and cost-effective way.
Nota: Número d'acord de subvenció ISCIII/FIS14/1775
Nota: Número d'acord de subvenció IWT/TBM/140191
Nota: Número d'acord de subvenció EC/FP7/260687
Nota: Número d'acord de subvenció EC/H2020/COST/BM1305
Drets: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. Creative Commons
Llengua: Anglès
Document: article ; recerca ; publishedVersion
Publicat a: Mediators of Inflammation, 2015, Article ID 471719, ISSN 0962-9351

DOI: 10.1155/2015/471719


9 p, 1.4 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats

 Registre creat el 2016-02-02, darrera modificació el 2016-10-06



   Favorit i Compartir